Active, not recruitingPhase 3NCT06003426
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Studying Idiopathic pulmonary fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bristol-Myers Squibb
- Principal Investigator
- Bristol-Myers SquibbBristol-Myers Squibb
- Intervention
- BMS-986278(drug)
- Enrollment
- 1255 enrolled
- Eligibility
- 40 years · All sexes
- Timeline
- 2023 – 2027
Study locations (30)
- Local Institution - 0189, Birmingham, Alabama, United States
- Local Institution - 0361, Phoenix, Arizona, United States
- Local Institution - 0396, La Jolla, California, United States
- Local Institution - 0193, Los Angeles, California, United States
- Local Institution - 0398, Los Angeles, California, United States
- Local Institution - 0389, Orange, California, United States
- Local Institution - 0405, Sacramento, California, United States
- Local Institution - 0185, San Francisco, California, United States
- Local Institution - 0186, Stanford, California, United States
- Local Institution - 0363, Aurora, Colorado, United States
- Local Institution - 0194, Denver, Colorado, United States
- Local Institution - 0175, New Haven, Connecticut, United States
- Local Institution - 0151, Newark, Delaware, United States
- Local Institution - 0367, Washington D.C., District of Columbia, United States
- Local Institution - 0101, Brandon, Florida, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06003426 on ClinicalTrials.govOther trials for Idiopathic pulmonary fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05988463Dose-Escalation Study of Artesunate Patients With IPFJoseph C. Wu
- RECRUITINGPHASE2NCT07572383Advanced Imaging to Assess the Effect of Immunosuppression on Progressive FibrosisPeter Caravan
- RECRUITINGNANCT07486206Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 TrialHospital de Granollers
- RECRUITINGNANCT07482917Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 TrialHospital de Granollers
- RECRUITINGPHASE2NCT06241560A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the BloodBoehringer Ingelheim
- RECRUITINGPHASE3NCT07201922A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisBoehringer Ingelheim
- RECRUITINGPHASE2NCT06968845A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary FibrosisRein Therapeutics
- ENROLLING BY INVITATIONNCT06885515Telomeres Length in Israeli Fibrotic ILD PatientsBarzilai Medical Center